NOTCH1: A therapeutic target for T cell acute lymphoblastic leukemia/lymphoma

V. Tosello, A. Ferrando

Research output: Contribution to journalArticle

Abstract

T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is an aggressive tumor that generally affects children but also arises in adults, affecting 1,500 people per year in the United States. T-ALL is often associated with hyperleucocytosis, large mediastinal masses and leptomeningeal infiltration at diagnosis. Activating mutations in NOTCH1 are present in about 50% of T-ALL cases and small molecule inhibitors of the γ-secretase complex (GSIs), which effectively abrogate NOTCH1 signaling, have been proposed for the treatment of T-ALL. Despite this interest, the clinical development of GSIs has been hampered by our incomplete understanding of the effector pathways controlled by NOTCH1, the lack of clinical responses to GSI therapy and the development of gastrointestinal toxicity secondary to inhibition of NOTCH signaling in the gut. However, recent studies have elucidated important downstream mechanisms of NOTCH1-induced transformation and uncovered the molecular basis of sensitivity and resistance to GSI therapy. Moreover, combination therapies of GSIs with glucocorticoids have been shown to induce potent antileukemic effects in glucocorticoid resistant T-ALL and to ameliorate the gastrointestinal toxicity associated with systemic inhibition of NOTCH signaling. These recent developments may lead to novel rationally-designed and highly effective therapies targeting NOTCH1 signaling in T-ALL.

Original languageEnglish
Pages (from-to)106-110
Number of pages5
JournalHaematologica Meeting Reports
Volume3
Issue number1
Publication statusPublished - 2009

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
T-Lymphocytes
Glucocorticoids
Therapeutics
Amyloid Precursor Protein Secretases
Mutation
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

NOTCH1 : A therapeutic target for T cell acute lymphoblastic leukemia/lymphoma. / Tosello, V.; Ferrando, A.

In: Haematologica Meeting Reports, Vol. 3, No. 1, 2009, p. 106-110.

Research output: Contribution to journalArticle

@article{2842094a9eff4763b02e7a98ea3b7276,
title = "NOTCH1: A therapeutic target for T cell acute lymphoblastic leukemia/lymphoma",
abstract = "T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is an aggressive tumor that generally affects children but also arises in adults, affecting 1,500 people per year in the United States. T-ALL is often associated with hyperleucocytosis, large mediastinal masses and leptomeningeal infiltration at diagnosis. Activating mutations in NOTCH1 are present in about 50{\%} of T-ALL cases and small molecule inhibitors of the γ-secretase complex (GSIs), which effectively abrogate NOTCH1 signaling, have been proposed for the treatment of T-ALL. Despite this interest, the clinical development of GSIs has been hampered by our incomplete understanding of the effector pathways controlled by NOTCH1, the lack of clinical responses to GSI therapy and the development of gastrointestinal toxicity secondary to inhibition of NOTCH signaling in the gut. However, recent studies have elucidated important downstream mechanisms of NOTCH1-induced transformation and uncovered the molecular basis of sensitivity and resistance to GSI therapy. Moreover, combination therapies of GSIs with glucocorticoids have been shown to induce potent antileukemic effects in glucocorticoid resistant T-ALL and to ameliorate the gastrointestinal toxicity associated with systemic inhibition of NOTCH signaling. These recent developments may lead to novel rationally-designed and highly effective therapies targeting NOTCH1 signaling in T-ALL.",
author = "V. Tosello and A. Ferrando",
year = "2009",
language = "English",
volume = "3",
pages = "106--110",
journal = "Haematologica Meeting Reports",
issn = "1970-7339",
publisher = "Ferrata Storti Foundation",
number = "1",

}

TY - JOUR

T1 - NOTCH1

T2 - A therapeutic target for T cell acute lymphoblastic leukemia/lymphoma

AU - Tosello, V.

AU - Ferrando, A.

PY - 2009

Y1 - 2009

N2 - T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is an aggressive tumor that generally affects children but also arises in adults, affecting 1,500 people per year in the United States. T-ALL is often associated with hyperleucocytosis, large mediastinal masses and leptomeningeal infiltration at diagnosis. Activating mutations in NOTCH1 are present in about 50% of T-ALL cases and small molecule inhibitors of the γ-secretase complex (GSIs), which effectively abrogate NOTCH1 signaling, have been proposed for the treatment of T-ALL. Despite this interest, the clinical development of GSIs has been hampered by our incomplete understanding of the effector pathways controlled by NOTCH1, the lack of clinical responses to GSI therapy and the development of gastrointestinal toxicity secondary to inhibition of NOTCH signaling in the gut. However, recent studies have elucidated important downstream mechanisms of NOTCH1-induced transformation and uncovered the molecular basis of sensitivity and resistance to GSI therapy. Moreover, combination therapies of GSIs with glucocorticoids have been shown to induce potent antileukemic effects in glucocorticoid resistant T-ALL and to ameliorate the gastrointestinal toxicity associated with systemic inhibition of NOTCH signaling. These recent developments may lead to novel rationally-designed and highly effective therapies targeting NOTCH1 signaling in T-ALL.

AB - T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is an aggressive tumor that generally affects children but also arises in adults, affecting 1,500 people per year in the United States. T-ALL is often associated with hyperleucocytosis, large mediastinal masses and leptomeningeal infiltration at diagnosis. Activating mutations in NOTCH1 are present in about 50% of T-ALL cases and small molecule inhibitors of the γ-secretase complex (GSIs), which effectively abrogate NOTCH1 signaling, have been proposed for the treatment of T-ALL. Despite this interest, the clinical development of GSIs has been hampered by our incomplete understanding of the effector pathways controlled by NOTCH1, the lack of clinical responses to GSI therapy and the development of gastrointestinal toxicity secondary to inhibition of NOTCH signaling in the gut. However, recent studies have elucidated important downstream mechanisms of NOTCH1-induced transformation and uncovered the molecular basis of sensitivity and resistance to GSI therapy. Moreover, combination therapies of GSIs with glucocorticoids have been shown to induce potent antileukemic effects in glucocorticoid resistant T-ALL and to ameliorate the gastrointestinal toxicity associated with systemic inhibition of NOTCH signaling. These recent developments may lead to novel rationally-designed and highly effective therapies targeting NOTCH1 signaling in T-ALL.

UR - http://www.scopus.com/inward/record.url?scp=69749087171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69749087171&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:69749087171

VL - 3

SP - 106

EP - 110

JO - Haematologica Meeting Reports

JF - Haematologica Meeting Reports

SN - 1970-7339

IS - 1

ER -